Literature DB >> 10512260

Determination of the effective therapeutic dose of intrathecal sufentanil for extracorporeal shock wave lithotripsy.

W C Lau1, C R Green, G J Faerber, A R Tait, J A Golembiewski.   

Abstract

UNLABELLED: Intrathecal (IT) sufentanil provides effective analgesia for extracorporeal shock wave lithotripsy. However, the optimal dose of sufentanil has not been established. We designed a prospective, randomized, double-blinded study to determine the optimal dose of IT sufentanil. Sixty men were randomized to receive 12.5,15,17.5, or 20 microg of IT sufentanil (n = 15 for each group) via a combined spinal epidural technique. Inadequate analgesia was treated with IV propofol, and the epidural was activated for a pain score greater than 6 on a 10-point verbal analog pain scale. Intraoperative and postoperative visual analog pain scale scores were significantly higher in the 12.5-microg group compared with 20-microg group (3.2 +/- 1.6 vs 1.6 +/- 1.2, P < 0.05, and 1.1 +/- 0.5 vs. 0.5 +/- 0.4, P < 0.05, respectively). The smaller-dosage groups of IT sufentanil required significantly more supplemental boluses of propofol compared with the 20-microg group (67%, 53%, and 40% vs 6%, respectively, P < 0.05). However, pruritus was significantly diminished in the smaller-dosage groups compared with the 20-microg group (55%, 60%, and 67% vs 100%, P < 0.05). The time to discharge was significantly shorter in the 15-microg group compared with the 20-microg group (84 +/- 40 min vs 126 +/- 48 min, P < 0.05). These results suggest that 15 microg of IT sufentanil may be the optimal IT dose for patients undergoing extracorporeal shock wave lithotripsy. IMPLICATIONS: Many anesthetic techniques are used for extracorporeal shock wave lithotripsy (ESWL). We have previously shown that intrathecal sufentanil was effective for ESWL, but was associated with a high incidence of itching. We tested 60 patients in four spinal sufentanil dose groups and found that doses of 15 and 17.5 microg provided the most effective analgesia with the fewest side effects for ESWL, with only mild itching.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512260     DOI: 10.1097/00000539-199910000-00013

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Topical EMLA for pain control during extracorporeal shock wave lithotripsy: prospective, comparative, randomized, double-blind study.

Authors:  D Gallego Vilar; G García Fadrique; C Di Capua Sacoto; J Beltran Persiva; M Perez Mestre; J A De Francia; I Povo Martin; J Miralles Aguado; C Garau Perelló; L Sanchis Verdu; J Gallego Gomez
Journal:  Urol Res       Date:  2012-05-04

Review 2.  Current developments in intraspinal agents for cancer and noncancer pain.

Authors:  Erin F Lawson; Mark S Wallace
Journal:  Curr Pain Headache Rep       Date:  2010-02

3.  Effect of sedation on pain perception.

Authors:  Michael A Frölich; Kui Zhang; Timothy J Ness
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

4.  Drugs for pain management in shock wave lithotripsy.

Authors:  Christian Bach; Faruquz Zaman; Stefanos Kachrilas; Priyadarshi Kumar; Noor Buchholz; Junaid Masood
Journal:  Pain Res Treat       Date:  2011-11-03

Review 5.  Analgesia for patients undergoing shockwave lithotripsy for urinary stones - a systematic review and meta-analysis.

Authors:  Omar M Aboumarzouk; Rami Hasan; Ali Tasleem; Martin Mariappan; Rachael Hutton; John Fitzpatrick; Laura Beatty; Gareth E Jones; Tarik Amer
Journal:  Int Braz J Urol       Date:  2017 May-Jun       Impact factor: 1.541

6.  Analgesia for pain control during extracorporeal shock wave lithotripsy: Current status.

Authors:  Narmada P Gupta; Anup Kumar
Journal:  Indian J Urol       Date:  2008-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.